PF-Atlas › Drugs › GB0139

GB0139

Idiopathic Pulmonary Fibrosis · Galectin-3 Inhibition

Clinical trials
2
Mechanism
Galectin-3 Inhibition
Developer
Galecto

Overview

GB0139 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via galectin-3 inhibition. It appears in 2 tracked IPF clinical trials.

GB0139 clinical trials

NCT-GB0139 (Phase 2)NCT03832946 (Phase 2)

Explore related

Galectin-3 InhibitionAll trialsResearch
Medical disclaimer. This page summarizes research about GB0139 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.